Oculis (NASDAQ:OCS) Posts Quarterly Earnings Results, Misses Estimates By $0.28 EPS

Oculis (NASDAQ:OCS) issued its earnings results on Tuesday. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.28), Zacks reports. Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%.

Oculis Stock Performance

Shares of OCS stock opened at $18.80 on Thursday. Oculis has a 12 month low of $10.55 and a 12 month high of $23.08. The stock has a market cap of $761.27 million, a PE ratio of -9.74 and a beta of 0.02. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The company’s fifty day moving average price is $20.86 and its 200-day moving average price is $16.88.

Analyst Upgrades and Downgrades

Several research analysts recently commented on OCS shares. Chardan Capital reaffirmed a “buy” rating and issued a $28.00 target price on shares of Oculis in a research note on Thursday. HC Wainwright cut their price target on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Robert W. Baird lifted their price target on shares of Oculis from $37.00 to $41.00 and gave the company an “outperform” rating in a report on Thursday.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.